Review





Similar Products

93
Miltenyi Biotec cd5 antibody, anti-mouse, reafinity
Cd5 Antibody, Anti Mouse, Reafinity, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd5 antibody, anti-mouse, reafinity/product/Miltenyi Biotec
Average 93 stars, based on 1 article reviews
cd5 antibody, anti-mouse, reafinity - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier

94
Sino Biological lnp mcd5
Lnp Mcd5, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lnp mcd5/product/Sino Biological
Average 94 stars, based on 1 article reviews
lnp mcd5 - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier

94
Miltenyi Biotec anti cd5 percp vio700
Anti Cd5 Percp Vio700, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti cd5 percp vio700/product/Miltenyi Biotec
Average 94 stars, based on 1 article reviews
anti cd5 percp vio700 - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier

99
Miltenyi Biotec cd2 cd3 cd5 cd7 pan t cells
Immunosuppressive capacity of circulating CD177 + S100A hi neutrophils. (A) Schematic representation of T cells and neutrophils co‐culture system. <t>CD3/CD28‐primed</t> pan‐T cells from healthy donors were co‐cultured in the absence or presence of CD177 + S100A hi neutrophils from G‐PB of early pregnancy. (B and C) Representative images of proliferative alterations (B, left), proportion of proliferative CD4 + T cells (B, right top) and CD8 + T cells (B, right bottom), secretion of TNF‐α (C, top) and IFN‐γ (C, bottom) in co‐cultures of pan‐T cells with or without CD177 + S100A hi ‐LDNs and CD177 + S100A hi ‐NDNs (ratio of 1:5) at Day 3.5 ( n = 7). Data are represented as mean ± SD. The symbol ‘–’ indicates T cells without <t>CD3/CD28</t> stimulation, whereas ‘+’ designates T cells primed with CD3/CD28. (D) Boxplot showing proportion of proliferative CD4 + T cells (left) and CD8 + T cells (right) in co‐cultures of pan‐T cells with CD177 + S100A hi ‐LDNs and CD177 + S100A hi ‐NDNs (ratio of 1:5) under a Transwell device at Day 3.5 ( n = 3). Data are represented as mean ± SD. (E) Quantification of apoptosis of CD4 + T cells and CD8 + T cells at a co‐culture ratio of 1:5 ( n = 4). Data are represented as mean ± SEM. (F) Enriched GO terms for the downregulated proteins in T cells from co‐cultures of pan‐T cells with CD177 + S100A hi ‐LDNs. The thickness of the string is proportional to LogFC. (G) Violin plot of average expression of co‐inhibitory receptor molecules TIGIT, TIM‐3, LAG‐3 and PSGL‐1 in T cells exposed to CD177 + S100A hi ‐LDNs compared with cultured alone. The y ‐axis represents the value of the log2 protein abundance. (H) L‐Arg concentration in supernatant from co‐cultures of pan‐T cells with or without CD177 + S100A hi ‐LDNs and CD177 + S100A hi ‐NDNs (ratio of 1:5) at Day 3.5 ( n = 7). Data are represented as mean ± SD. (I and J) The proportion of proliferative CD4 + T cells (left) and CD8 + T cells (right) in co‐cultures of pan‐T cells with or without CD177 + S100A hi ‐LDNs and CD177 + S100A hi ‐NDNs (ratio of 1:5), with or without: 200 µg/mL L‐Arg (I); 200 U/mL CAT (J, top); 2 mM NAC (J, bottom). Data are represented as mean ± SD. p ‐values are calculated using the one‐way ANOVA with Tukey's post hoc test and Student's t ‐test. G‐PB, G‐CSF‐mobilised peripheral blood; LDNs, low density neutrophils; NDNs, normal density neutrophils; TNF‐α, tumour necrosis factor‐α; IFN‐γ, interferon‐γ; ARG1, arginase 1; ROS, reactive oxygen species; L‐Arg, L‐arginine; CAT, catalase.
Cd2 Cd3 Cd5 Cd7 Pan T Cells, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd2 cd3 cd5 cd7 pan t cells/product/Miltenyi Biotec
Average 99 stars, based on 1 article reviews
cd2 cd3 cd5 cd7 pan t cells - by Bioz Stars, 2026-02
99/100 stars
  Buy from Supplier

cd5  (Bio-Rad)
93
Bio-Rad cd5
Immunosuppressive capacity of circulating CD177 + S100A hi neutrophils. (A) Schematic representation of T cells and neutrophils co‐culture system. <t>CD3/CD28‐primed</t> pan‐T cells from healthy donors were co‐cultured in the absence or presence of CD177 + S100A hi neutrophils from G‐PB of early pregnancy. (B and C) Representative images of proliferative alterations (B, left), proportion of proliferative CD4 + T cells (B, right top) and CD8 + T cells (B, right bottom), secretion of TNF‐α (C, top) and IFN‐γ (C, bottom) in co‐cultures of pan‐T cells with or without CD177 + S100A hi ‐LDNs and CD177 + S100A hi ‐NDNs (ratio of 1:5) at Day 3.5 ( n = 7). Data are represented as mean ± SD. The symbol ‘–’ indicates T cells without <t>CD3/CD28</t> stimulation, whereas ‘+’ designates T cells primed with CD3/CD28. (D) Boxplot showing proportion of proliferative CD4 + T cells (left) and CD8 + T cells (right) in co‐cultures of pan‐T cells with CD177 + S100A hi ‐LDNs and CD177 + S100A hi ‐NDNs (ratio of 1:5) under a Transwell device at Day 3.5 ( n = 3). Data are represented as mean ± SD. (E) Quantification of apoptosis of CD4 + T cells and CD8 + T cells at a co‐culture ratio of 1:5 ( n = 4). Data are represented as mean ± SEM. (F) Enriched GO terms for the downregulated proteins in T cells from co‐cultures of pan‐T cells with CD177 + S100A hi ‐LDNs. The thickness of the string is proportional to LogFC. (G) Violin plot of average expression of co‐inhibitory receptor molecules TIGIT, TIM‐3, LAG‐3 and PSGL‐1 in T cells exposed to CD177 + S100A hi ‐LDNs compared with cultured alone. The y ‐axis represents the value of the log2 protein abundance. (H) L‐Arg concentration in supernatant from co‐cultures of pan‐T cells with or without CD177 + S100A hi ‐LDNs and CD177 + S100A hi ‐NDNs (ratio of 1:5) at Day 3.5 ( n = 7). Data are represented as mean ± SD. (I and J) The proportion of proliferative CD4 + T cells (left) and CD8 + T cells (right) in co‐cultures of pan‐T cells with or without CD177 + S100A hi ‐LDNs and CD177 + S100A hi ‐NDNs (ratio of 1:5), with or without: 200 µg/mL L‐Arg (I); 200 U/mL CAT (J, top); 2 mM NAC (J, bottom). Data are represented as mean ± SD. p ‐values are calculated using the one‐way ANOVA with Tukey's post hoc test and Student's t ‐test. G‐PB, G‐CSF‐mobilised peripheral blood; LDNs, low density neutrophils; NDNs, normal density neutrophils; TNF‐α, tumour necrosis factor‐α; IFN‐γ, interferon‐γ; ARG1, arginase 1; ROS, reactive oxygen species; L‐Arg, L‐arginine; CAT, catalase.
Cd5, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd5/product/Bio-Rad
Average 93 stars, based on 1 article reviews
cd5 - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier

98
Miltenyi Biotec cd5 cd45r cd11b gr1 7 4
S100A9‐inhibition using tasquinimod reveals novel transcriptome reprogramming and reversal of TGFβ activation. (A) Experimental scheme of RNAseq sorting strategy for JAK2 WT or JAK2 V617F CD41 + , <t>CD11b</t> + <t>Gr1</t> − , and Lin − Sca1 + cells, either treated with vehicle or tasquinimod ( n = 3 mice/group/cell population). (B) Principal component analysis of JAK2 WT or JAK2 V617F CD41 + , CD11b + Gr1 − , and Lin − Sca1 + cells, either treated with vehicle or tasquinimod. (C) Heatmap representation of PROGENy analysis in CD41 + , CD11b + Gr1 − , and Lin − Sca1 + cells. (D) Heatmap representation of extracellular matrix (ECM)‐related Hallmark pathways in CD41 + , CD11b + Gr1 − , and Lin − Sca1 + cells, comparing JAK2 V617F vehicle versus JAK2 WT vehicle (labeled as “V617F veh”) and JAK2 V617F tasquinimod versus JAK2 V617F vehicle (labeled as “V617F Tasq”). (E) Overall cell‐to‐cell interactions between CD41 + , CD11b + Gr1 − , and Lin − Sca1 + cells. (F) Top 30 deregulated interactions mediated by TGFB1 between CD41 + , CD11b + Gr1 − , and Lin − Sca1 + cells. Interactions ordered based on the difference in mean LR expression between JAK2 V617F tasquinimod and JAK2 V617F vehicle.
Cd5 Cd45r Cd11b Gr1 7 4, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd5 cd45r cd11b gr1 7 4/product/Miltenyi Biotec
Average 98 stars, based on 1 article reviews
cd5 cd45r cd11b gr1 7 4 - by Bioz Stars, 2026-02
98/100 stars
  Buy from Supplier

93
fluidigm 3143007c
S100A9‐inhibition using tasquinimod reveals novel transcriptome reprogramming and reversal of TGFβ activation. (A) Experimental scheme of RNAseq sorting strategy for JAK2 WT or JAK2 V617F CD41 + , <t>CD11b</t> + <t>Gr1</t> − , and Lin − Sca1 + cells, either treated with vehicle or tasquinimod ( n = 3 mice/group/cell population). (B) Principal component analysis of JAK2 WT or JAK2 V617F CD41 + , CD11b + Gr1 − , and Lin − Sca1 + cells, either treated with vehicle or tasquinimod. (C) Heatmap representation of PROGENy analysis in CD41 + , CD11b + Gr1 − , and Lin − Sca1 + cells. (D) Heatmap representation of extracellular matrix (ECM)‐related Hallmark pathways in CD41 + , CD11b + Gr1 − , and Lin − Sca1 + cells, comparing JAK2 V617F vehicle versus JAK2 WT vehicle (labeled as “V617F veh”) and JAK2 V617F tasquinimod versus JAK2 V617F vehicle (labeled as “V617F Tasq”). (E) Overall cell‐to‐cell interactions between CD41 + , CD11b + Gr1 − , and Lin − Sca1 + cells. (F) Top 30 deregulated interactions mediated by TGFB1 between CD41 + , CD11b + Gr1 − , and Lin − Sca1 + cells. Interactions ordered based on the difference in mean LR expression between JAK2 V617F tasquinimod and JAK2 V617F vehicle.
3143007c, supplied by fluidigm, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/3143007c/product/fluidigm
Average 93 stars, based on 1 article reviews
3143007c - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier




Image Search Results


Immunosuppressive capacity of circulating CD177 + S100A hi neutrophils. (A) Schematic representation of T cells and neutrophils co‐culture system. CD3/CD28‐primed pan‐T cells from healthy donors were co‐cultured in the absence or presence of CD177 + S100A hi neutrophils from G‐PB of early pregnancy. (B and C) Representative images of proliferative alterations (B, left), proportion of proliferative CD4 + T cells (B, right top) and CD8 + T cells (B, right bottom), secretion of TNF‐α (C, top) and IFN‐γ (C, bottom) in co‐cultures of pan‐T cells with or without CD177 + S100A hi ‐LDNs and CD177 + S100A hi ‐NDNs (ratio of 1:5) at Day 3.5 ( n = 7). Data are represented as mean ± SD. The symbol ‘–’ indicates T cells without CD3/CD28 stimulation, whereas ‘+’ designates T cells primed with CD3/CD28. (D) Boxplot showing proportion of proliferative CD4 + T cells (left) and CD8 + T cells (right) in co‐cultures of pan‐T cells with CD177 + S100A hi ‐LDNs and CD177 + S100A hi ‐NDNs (ratio of 1:5) under a Transwell device at Day 3.5 ( n = 3). Data are represented as mean ± SD. (E) Quantification of apoptosis of CD4 + T cells and CD8 + T cells at a co‐culture ratio of 1:5 ( n = 4). Data are represented as mean ± SEM. (F) Enriched GO terms for the downregulated proteins in T cells from co‐cultures of pan‐T cells with CD177 + S100A hi ‐LDNs. The thickness of the string is proportional to LogFC. (G) Violin plot of average expression of co‐inhibitory receptor molecules TIGIT, TIM‐3, LAG‐3 and PSGL‐1 in T cells exposed to CD177 + S100A hi ‐LDNs compared with cultured alone. The y ‐axis represents the value of the log2 protein abundance. (H) L‐Arg concentration in supernatant from co‐cultures of pan‐T cells with or without CD177 + S100A hi ‐LDNs and CD177 + S100A hi ‐NDNs (ratio of 1:5) at Day 3.5 ( n = 7). Data are represented as mean ± SD. (I and J) The proportion of proliferative CD4 + T cells (left) and CD8 + T cells (right) in co‐cultures of pan‐T cells with or without CD177 + S100A hi ‐LDNs and CD177 + S100A hi ‐NDNs (ratio of 1:5), with or without: 200 µg/mL L‐Arg (I); 200 U/mL CAT (J, top); 2 mM NAC (J, bottom). Data are represented as mean ± SD. p ‐values are calculated using the one‐way ANOVA with Tukey's post hoc test and Student's t ‐test. G‐PB, G‐CSF‐mobilised peripheral blood; LDNs, low density neutrophils; NDNs, normal density neutrophils; TNF‐α, tumour necrosis factor‐α; IFN‐γ, interferon‐γ; ARG1, arginase 1; ROS, reactive oxygen species; L‐Arg, L‐arginine; CAT, catalase.

Journal: Clinical and Translational Medicine

Article Title: Granulocyte colony‐stimulating factor induced T‐cell hyporesponsiveness via modulation of CD177 + S100A hi neutrophils in unexplained recurrent pregnancy loss

doi: 10.1002/ctm2.70508

Figure Lengend Snippet: Immunosuppressive capacity of circulating CD177 + S100A hi neutrophils. (A) Schematic representation of T cells and neutrophils co‐culture system. CD3/CD28‐primed pan‐T cells from healthy donors were co‐cultured in the absence or presence of CD177 + S100A hi neutrophils from G‐PB of early pregnancy. (B and C) Representative images of proliferative alterations (B, left), proportion of proliferative CD4 + T cells (B, right top) and CD8 + T cells (B, right bottom), secretion of TNF‐α (C, top) and IFN‐γ (C, bottom) in co‐cultures of pan‐T cells with or without CD177 + S100A hi ‐LDNs and CD177 + S100A hi ‐NDNs (ratio of 1:5) at Day 3.5 ( n = 7). Data are represented as mean ± SD. The symbol ‘–’ indicates T cells without CD3/CD28 stimulation, whereas ‘+’ designates T cells primed with CD3/CD28. (D) Boxplot showing proportion of proliferative CD4 + T cells (left) and CD8 + T cells (right) in co‐cultures of pan‐T cells with CD177 + S100A hi ‐LDNs and CD177 + S100A hi ‐NDNs (ratio of 1:5) under a Transwell device at Day 3.5 ( n = 3). Data are represented as mean ± SD. (E) Quantification of apoptosis of CD4 + T cells and CD8 + T cells at a co‐culture ratio of 1:5 ( n = 4). Data are represented as mean ± SEM. (F) Enriched GO terms for the downregulated proteins in T cells from co‐cultures of pan‐T cells with CD177 + S100A hi ‐LDNs. The thickness of the string is proportional to LogFC. (G) Violin plot of average expression of co‐inhibitory receptor molecules TIGIT, TIM‐3, LAG‐3 and PSGL‐1 in T cells exposed to CD177 + S100A hi ‐LDNs compared with cultured alone. The y ‐axis represents the value of the log2 protein abundance. (H) L‐Arg concentration in supernatant from co‐cultures of pan‐T cells with or without CD177 + S100A hi ‐LDNs and CD177 + S100A hi ‐NDNs (ratio of 1:5) at Day 3.5 ( n = 7). Data are represented as mean ± SD. (I and J) The proportion of proliferative CD4 + T cells (left) and CD8 + T cells (right) in co‐cultures of pan‐T cells with or without CD177 + S100A hi ‐LDNs and CD177 + S100A hi ‐NDNs (ratio of 1:5), with or without: 200 µg/mL L‐Arg (I); 200 U/mL CAT (J, top); 2 mM NAC (J, bottom). Data are represented as mean ± SD. p ‐values are calculated using the one‐way ANOVA with Tukey's post hoc test and Student's t ‐test. G‐PB, G‐CSF‐mobilised peripheral blood; LDNs, low density neutrophils; NDNs, normal density neutrophils; TNF‐α, tumour necrosis factor‐α; IFN‐γ, interferon‐γ; ARG1, arginase 1; ROS, reactive oxygen species; L‐Arg, L‐arginine; CAT, catalase.

Article Snippet: CD2 + CD3 + CD5 + CD7 + ‐pan‐T cells were collected from the PBMCs of healthy donors using the ‘Pan‐T‐cell Isolation kit’ (Miltenyi Biotec) and Lymphoprep (Stemcell).

Techniques: Co-Culture Assay, Cell Culture, Expressing, Quantitative Proteomics, Concentration Assay

Diminished CD177 + S100A hi neutrophils in PB of URPL. (A) Representative flow cytometry plots showing distribution of neutrophils in PBMCs and NDNs layers of HCs, patients with URPL and URPL receiving G‐CSF treatment. NDNs and LDNs are gated based on CD45 and side‐scatter properties in PBMCs and NDNs fractions, respectively. Reliable neutrophils are identified as CD15 + cells among NDNs/LDNs. (B) Representative flow cytometry plots and quantification showing percentage of CD177 + S100A hi ‐LDNs in HCs and URPL patients receiving G‐CSF treatment ( n = 8/each group). Data are represented as mean ± SD. (C) Representative flow cytometry plots and quantification showing percentage of CD177 + S100A hi ‐NDNs in HCs ( n = 8), patients with URPL ( n = 6) and URPL receiving G‐CSF treatment ( n = 8). Data are represented as mean ± SD. (D) Flow cytometry of ARG1 expression in HC, patients with URPL and URPL receiving G‐CSF treatment ( n = 5/each group). Data are represented as mean ± SD. (E) Serum L‐Arg concentrations in HCs ( n = 13), patients with URPL ( n = 18) and URPL receiving G‐CSF treatment ( n = 18). Data are represented as mean ± SD. (F) The percentage of circulating neutrophils detected in PB before and after G‐CSF administration ( n = 16/each group). (G) Relative mRNA expression of CD177, S100A8, S100A9 and S100A12 between G‐CSF‐mobilised and non‐mobilised neutrophils ( n = 16/each group). (H) The percentage of circulating CD3 + T cells detected in PBMCs before and after G‐CSF administration ( n = 8/each group). (I) Expression of inflammation‐related factors TNF‐α, IFN‐γ, IL‐6 and IL‐1β in pregnant women with URPL history before and after G‐CSF administration ( n = 13/each group). p ‐values are calculated using the one‐way ANOVA with Tukey's post hoc test and Student's t ‐test. PBMCs, peripheral blood mononuclear cells; HCs, healthy pregnant controls; URPL, unexplained recurrent pregnancy loss; LDNs, low density neutrophils; NDNs, normal density neutrophils; ARG1, arginase 1; MFI, mean fluorescence intensity; L‐Arg, L‐arginine; TNF‐α, tumour necrosis factor‐α; IFN‐γ, interferon‐γ; IL‐6, interleukin‐6.

Journal: Clinical and Translational Medicine

Article Title: Granulocyte colony‐stimulating factor induced T‐cell hyporesponsiveness via modulation of CD177 + S100A hi neutrophils in unexplained recurrent pregnancy loss

doi: 10.1002/ctm2.70508

Figure Lengend Snippet: Diminished CD177 + S100A hi neutrophils in PB of URPL. (A) Representative flow cytometry plots showing distribution of neutrophils in PBMCs and NDNs layers of HCs, patients with URPL and URPL receiving G‐CSF treatment. NDNs and LDNs are gated based on CD45 and side‐scatter properties in PBMCs and NDNs fractions, respectively. Reliable neutrophils are identified as CD15 + cells among NDNs/LDNs. (B) Representative flow cytometry plots and quantification showing percentage of CD177 + S100A hi ‐LDNs in HCs and URPL patients receiving G‐CSF treatment ( n = 8/each group). Data are represented as mean ± SD. (C) Representative flow cytometry plots and quantification showing percentage of CD177 + S100A hi ‐NDNs in HCs ( n = 8), patients with URPL ( n = 6) and URPL receiving G‐CSF treatment ( n = 8). Data are represented as mean ± SD. (D) Flow cytometry of ARG1 expression in HC, patients with URPL and URPL receiving G‐CSF treatment ( n = 5/each group). Data are represented as mean ± SD. (E) Serum L‐Arg concentrations in HCs ( n = 13), patients with URPL ( n = 18) and URPL receiving G‐CSF treatment ( n = 18). Data are represented as mean ± SD. (F) The percentage of circulating neutrophils detected in PB before and after G‐CSF administration ( n = 16/each group). (G) Relative mRNA expression of CD177, S100A8, S100A9 and S100A12 between G‐CSF‐mobilised and non‐mobilised neutrophils ( n = 16/each group). (H) The percentage of circulating CD3 + T cells detected in PBMCs before and after G‐CSF administration ( n = 8/each group). (I) Expression of inflammation‐related factors TNF‐α, IFN‐γ, IL‐6 and IL‐1β in pregnant women with URPL history before and after G‐CSF administration ( n = 13/each group). p ‐values are calculated using the one‐way ANOVA with Tukey's post hoc test and Student's t ‐test. PBMCs, peripheral blood mononuclear cells; HCs, healthy pregnant controls; URPL, unexplained recurrent pregnancy loss; LDNs, low density neutrophils; NDNs, normal density neutrophils; ARG1, arginase 1; MFI, mean fluorescence intensity; L‐Arg, L‐arginine; TNF‐α, tumour necrosis factor‐α; IFN‐γ, interferon‐γ; IL‐6, interleukin‐6.

Article Snippet: CD2 + CD3 + CD5 + CD7 + ‐pan‐T cells were collected from the PBMCs of healthy donors using the ‘Pan‐T‐cell Isolation kit’ (Miltenyi Biotec) and Lymphoprep (Stemcell).

Techniques: Flow Cytometry, Expressing, Fluorescence

S100A9‐inhibition using tasquinimod reveals novel transcriptome reprogramming and reversal of TGFβ activation. (A) Experimental scheme of RNAseq sorting strategy for JAK2 WT or JAK2 V617F CD41 + , CD11b + Gr1 − , and Lin − Sca1 + cells, either treated with vehicle or tasquinimod ( n = 3 mice/group/cell population). (B) Principal component analysis of JAK2 WT or JAK2 V617F CD41 + , CD11b + Gr1 − , and Lin − Sca1 + cells, either treated with vehicle or tasquinimod. (C) Heatmap representation of PROGENy analysis in CD41 + , CD11b + Gr1 − , and Lin − Sca1 + cells. (D) Heatmap representation of extracellular matrix (ECM)‐related Hallmark pathways in CD41 + , CD11b + Gr1 − , and Lin − Sca1 + cells, comparing JAK2 V617F vehicle versus JAK2 WT vehicle (labeled as “V617F veh”) and JAK2 V617F tasquinimod versus JAK2 V617F vehicle (labeled as “V617F Tasq”). (E) Overall cell‐to‐cell interactions between CD41 + , CD11b + Gr1 − , and Lin − Sca1 + cells. (F) Top 30 deregulated interactions mediated by TGFB1 between CD41 + , CD11b + Gr1 − , and Lin − Sca1 + cells. Interactions ordered based on the difference in mean LR expression between JAK2 V617F tasquinimod and JAK2 V617F vehicle.

Journal: HemaSphere

Article Title: Inhibiting the alarmin‐driven hematopoiesis‐stromal cell crosstalk in primary myelofibrosis ameliorates bone marrow fibrosis

doi: 10.1002/hem3.70179

Figure Lengend Snippet: S100A9‐inhibition using tasquinimod reveals novel transcriptome reprogramming and reversal of TGFβ activation. (A) Experimental scheme of RNAseq sorting strategy for JAK2 WT or JAK2 V617F CD41 + , CD11b + Gr1 − , and Lin − Sca1 + cells, either treated with vehicle or tasquinimod ( n = 3 mice/group/cell population). (B) Principal component analysis of JAK2 WT or JAK2 V617F CD41 + , CD11b + Gr1 − , and Lin − Sca1 + cells, either treated with vehicle or tasquinimod. (C) Heatmap representation of PROGENy analysis in CD41 + , CD11b + Gr1 − , and Lin − Sca1 + cells. (D) Heatmap representation of extracellular matrix (ECM)‐related Hallmark pathways in CD41 + , CD11b + Gr1 − , and Lin − Sca1 + cells, comparing JAK2 V617F vehicle versus JAK2 WT vehicle (labeled as “V617F veh”) and JAK2 V617F tasquinimod versus JAK2 V617F vehicle (labeled as “V617F Tasq”). (E) Overall cell‐to‐cell interactions between CD41 + , CD11b + Gr1 − , and Lin − Sca1 + cells. (F) Top 30 deregulated interactions mediated by TGFB1 between CD41 + , CD11b + Gr1 − , and Lin − Sca1 + cells. Interactions ordered based on the difference in mean LR expression between JAK2 V617F tasquinimod and JAK2 V617F vehicle.

Article Snippet: The cells were lineage‐depleted using biotinylated antibodies directed against lineages (CD5, CD45R, CD11b, Gr1, 7‐4, and Ter119) (Miltenyi Biotec) and additionally added CD45‐ and CD71‐biotin antibodies (BioLegend).

Techniques: Inhibition, Activation Assay, Labeling, Expressing

Tasquinimod treatment abrogates Myc activation and induces JAK2 V617F ‐specific apoptosis. (A) Hallmark gene set enrichment analysis (GSEA) of Gr1 − CD11b + monocytes and (B) Lin − Sca1 + stromal cells, comparing JAK2V617F vehicle versus JAK2WT vehicle (labeled as “V617F vehicle”) and JAK2V617F tasquinimod versus JAK2V617F vehicle (labeled as “V617F tasquinimod”). (C) Frequency of GFP + cells in peripheral blood over time. (D) Flow analysis of early‐stage cell apoptosis (Annexin V + ), and late‐stage apoptosis (Annexin V + 7‐AAD + ) in JAK2 WT ‐HoxB8‐Flt3 or JAK2 V617F ‐HoxB8‐Flt3 cells treated with 50 µM tasquinimod or DMSO control for 24 h. (E) Heatmaps of differential analysis focused on damage‐associated molecular pattern (DAMP)‐associated genes. All comparisons are JAK2 V617F vehicle versus JAK2 WT vehicle (labeled as “V617F vehicle”) and JAK2 V617F tasquinimod versus JAK2 V617F vehicle (labeled as “V617F tasquinimod”). (F) Enzyme‐linked immunosorbent assay (ELISA) analysis of the S100A8/S100A9 heterodimer on murine plasma samples from JAK2 WT or JAK2 V617F animals, either treated with vehicle or tasquinimod drinking water ( n = 7–10/group). (G) Sankey plot showing S100a8‐Tlr4 ligand–receptor interactions in Gr1 − CD11b + monocytes. (H) CARNIVAL‐based pathway inference of the effect of S100a8/S100a9 binding to Tlr4.

Journal: HemaSphere

Article Title: Inhibiting the alarmin‐driven hematopoiesis‐stromal cell crosstalk in primary myelofibrosis ameliorates bone marrow fibrosis

doi: 10.1002/hem3.70179

Figure Lengend Snippet: Tasquinimod treatment abrogates Myc activation and induces JAK2 V617F ‐specific apoptosis. (A) Hallmark gene set enrichment analysis (GSEA) of Gr1 − CD11b + monocytes and (B) Lin − Sca1 + stromal cells, comparing JAK2V617F vehicle versus JAK2WT vehicle (labeled as “V617F vehicle”) and JAK2V617F tasquinimod versus JAK2V617F vehicle (labeled as “V617F tasquinimod”). (C) Frequency of GFP + cells in peripheral blood over time. (D) Flow analysis of early‐stage cell apoptosis (Annexin V + ), and late‐stage apoptosis (Annexin V + 7‐AAD + ) in JAK2 WT ‐HoxB8‐Flt3 or JAK2 V617F ‐HoxB8‐Flt3 cells treated with 50 µM tasquinimod or DMSO control for 24 h. (E) Heatmaps of differential analysis focused on damage‐associated molecular pattern (DAMP)‐associated genes. All comparisons are JAK2 V617F vehicle versus JAK2 WT vehicle (labeled as “V617F vehicle”) and JAK2 V617F tasquinimod versus JAK2 V617F vehicle (labeled as “V617F tasquinimod”). (F) Enzyme‐linked immunosorbent assay (ELISA) analysis of the S100A8/S100A9 heterodimer on murine plasma samples from JAK2 WT or JAK2 V617F animals, either treated with vehicle or tasquinimod drinking water ( n = 7–10/group). (G) Sankey plot showing S100a8‐Tlr4 ligand–receptor interactions in Gr1 − CD11b + monocytes. (H) CARNIVAL‐based pathway inference of the effect of S100a8/S100a9 binding to Tlr4.

Article Snippet: The cells were lineage‐depleted using biotinylated antibodies directed against lineages (CD5, CD45R, CD11b, Gr1, 7‐4, and Ter119) (Miltenyi Biotec) and additionally added CD45‐ and CD71‐biotin antibodies (BioLegend).

Techniques: Activation Assay, Labeling, Control, Enzyme-linked Immunosorbent Assay, Clinical Proteomics, Binding Assay

ProTcell’s subsets express innate lymphoid cell markers delineating a second cell fate. ProTcells were produced from mPB and CB CD34 + cells through an ex vivo system and their transcriptome (scRNAseq) or protein expression (CyTOF) were assessed in a single cell fashion, and restricted to CD7 + progenitors, as described in <xref ref-type= Figures 1A, B . Violin plots showing the normalized expression level of (A) ILC- and (B) NK-related genes in the 7 clusters. Density plots illustrating the gene expression of (C) the main ILC markers KLRB1, ID2, NFIL3 and KIT and (D) NK-related markers GZMA, GZMB, PRF1 and CD56. (E) CyTOF data was visualized by UMAP dimension reduction technic. UMAP projections illustrating the protein expression of CD7, CD161, KIT and CD5. The green line delineates the CD161-expressing cells along with KIT enrichment, i.e. the ILC-primed cells; the red contour excludes the CD161-expressing cells and includes CD5 + progenitors. (F) UMAP projection showing the pseudotime lineages calculated by Slingshot that describes the progressive transition along CD7 + clusters. " width="100%" height="100%">

Journal: Frontiers in Immunology

Article Title: Ex vivo- generated lymphoid progenitors encompass both T cell and innate lymphoid cell fates

doi: 10.3389/fimmu.2025.1617707

Figure Lengend Snippet: ProTcell’s subsets express innate lymphoid cell markers delineating a second cell fate. ProTcells were produced from mPB and CB CD34 + cells through an ex vivo system and their transcriptome (scRNAseq) or protein expression (CyTOF) were assessed in a single cell fashion, and restricted to CD7 + progenitors, as described in Figures 1A, B . Violin plots showing the normalized expression level of (A) ILC- and (B) NK-related genes in the 7 clusters. Density plots illustrating the gene expression of (C) the main ILC markers KLRB1, ID2, NFIL3 and KIT and (D) NK-related markers GZMA, GZMB, PRF1 and CD56. (E) CyTOF data was visualized by UMAP dimension reduction technic. UMAP projections illustrating the protein expression of CD7, CD161, KIT and CD5. The green line delineates the CD161-expressing cells along with KIT enrichment, i.e. the ILC-primed cells; the red contour excludes the CD161-expressing cells and includes CD5 + progenitors. (F) UMAP projection showing the pseudotime lineages calculated by Slingshot that describes the progressive transition along CD7 + clusters.

Article Snippet: 143Nd , CD5 , Fluidigm , UCHT2 , 3143007C.

Techniques: Produced, Ex Vivo, Expressing, Gene Expression

Activation of BCL11B regulatory elements does not restrict NK cell potential. (A) Experimental design for assessing BCL11B role in human T cell commitment. EGFP-BAC reporter was integrated at exon 1 of endogenous BCL11B gene in hPSC, resulting in a monoallelic disruption of this gene and the creation of BCL11B -EGFP reporter cell line. BCL11B -EGFP hPSCs were differentiated into hematopoietic progenitors (HP) for 9 days. The generated HP cells were isolated for early T cell differentiation on OP9-DLL4 for 14 more days. At this time, T9+T14, BCL11B -EGFP negative and positive progenitor cells had been sorted by FACS and secondary cultures were performed to assess their myeloid, NK and T cell potential. Phenotypes were assessed at each stage by flow cytometry for myeloid, lymphoid, NK or T membrane markers. (B) Representative dot plot of flow cytometry analysis of BCL11B -EGFP hPSC-derived progenitors upon sorting at day T9+T14 after culture on OP9-DLL4 for 14 days. At this stage, CD45 + CD56 - CD7 + cells are clearly distributed into two populations, according to BCL11B -EGFP expression. (C, D) BCL11B-EGFP neg/+ progenitors were co-cultured for 10 days with OP9-DLL4 with IL15 for NK differentiation. (C) Representative contour plots of flow cytometry analysis illustrating the expression of CD56, delineating NK differentiation, and CD16, translating NK maturation. (D) Bar plot representing the mean ± SD of CD56-expressing NK-primed cells in three independent experiments. *p<0.05 values are for paired Student’s t-test. (E, F) BCL11B -EGFP neg/+ progenitors were co-cultured 5 days with OP9 for myeloid differentiation. (E) Representative contour plots of flow cytometry analysis illustrating CD11b expression translating myeloid priming. (F) Bar plot representing the mean ± SD of CD11b-expressing myeloid progenitors in three independent experiments. *p<0.05 values are for paired Student’s t-test. (G, H) BCL11B -EGFP neg/+ progenitors were co-cultured 7 days with OP9-DLL4 devoid of IL15 for T cell differentiation. (G) Representative contour plots of flow cytometry analysis illustrating the expression of CD7 and CD5 translating T cell differentiation. (F) Bar plot representing the mean ± SD of CD7 and CD5-expressing T cell progenitor cells in four independent experiments.

Journal: Frontiers in Immunology

Article Title: Ex vivo- generated lymphoid progenitors encompass both T cell and innate lymphoid cell fates

doi: 10.3389/fimmu.2025.1617707

Figure Lengend Snippet: Activation of BCL11B regulatory elements does not restrict NK cell potential. (A) Experimental design for assessing BCL11B role in human T cell commitment. EGFP-BAC reporter was integrated at exon 1 of endogenous BCL11B gene in hPSC, resulting in a monoallelic disruption of this gene and the creation of BCL11B -EGFP reporter cell line. BCL11B -EGFP hPSCs were differentiated into hematopoietic progenitors (HP) for 9 days. The generated HP cells were isolated for early T cell differentiation on OP9-DLL4 for 14 more days. At this time, T9+T14, BCL11B -EGFP negative and positive progenitor cells had been sorted by FACS and secondary cultures were performed to assess their myeloid, NK and T cell potential. Phenotypes were assessed at each stage by flow cytometry for myeloid, lymphoid, NK or T membrane markers. (B) Representative dot plot of flow cytometry analysis of BCL11B -EGFP hPSC-derived progenitors upon sorting at day T9+T14 after culture on OP9-DLL4 for 14 days. At this stage, CD45 + CD56 - CD7 + cells are clearly distributed into two populations, according to BCL11B -EGFP expression. (C, D) BCL11B-EGFP neg/+ progenitors were co-cultured for 10 days with OP9-DLL4 with IL15 for NK differentiation. (C) Representative contour plots of flow cytometry analysis illustrating the expression of CD56, delineating NK differentiation, and CD16, translating NK maturation. (D) Bar plot representing the mean ± SD of CD56-expressing NK-primed cells in three independent experiments. *p<0.05 values are for paired Student’s t-test. (E, F) BCL11B -EGFP neg/+ progenitors were co-cultured 5 days with OP9 for myeloid differentiation. (E) Representative contour plots of flow cytometry analysis illustrating CD11b expression translating myeloid priming. (F) Bar plot representing the mean ± SD of CD11b-expressing myeloid progenitors in three independent experiments. *p<0.05 values are for paired Student’s t-test. (G, H) BCL11B -EGFP neg/+ progenitors were co-cultured 7 days with OP9-DLL4 devoid of IL15 for T cell differentiation. (G) Representative contour plots of flow cytometry analysis illustrating the expression of CD7 and CD5 translating T cell differentiation. (F) Bar plot representing the mean ± SD of CD7 and CD5-expressing T cell progenitor cells in four independent experiments.

Article Snippet: 143Nd , CD5 , Fluidigm , UCHT2 , 3143007C.

Techniques: Activation Assay, Disruption, Generated, Isolation, Cell Differentiation, Flow Cytometry, Membrane, Derivative Assay, Expressing, Cell Culture